Trial Profile

A phase 3 clinical study assessing orismilast

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 10 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Orismilast (Primary)
Indications Atopic dermatitis; Hidradenitis suppurativa; Plaque psoriasis
Focus Registrational; Therapeutic Use
Sponsors UNION Therapeutics

Most Recent Events

04 Jun 2024 According to an Union Therapeutics media release, the company has scheduled an End of Phase 2 meeting with the FDA to discuss advancing the orismilast development program into Phase 3 studies in AD.
09 Jan 2023 According to Union Therapeutics media release, the topline results are expected later in 2023.
09 Aug 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com